Selumetinib - Generic Drug Details
✉ Email this page to a colleague
US Patents and Regulatory Information for Selumetinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | KOSELUGO | selumetinib sulfate | CAPSULE;ORAL | 213756-001 | Apr 10, 2020 | RX | Yes | No | 9,562,017 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Astrazeneca | KOSELUGO | selumetinib sulfate | GRANULE;ORAL | 219943-002 | Sep 10, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astrazeneca | KOSELUGO | selumetinib sulfate | GRANULE;ORAL | 219943-001 | Sep 10, 2025 | RX | Yes | No | 7,425,637 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Astrazeneca | KOSELUGO | selumetinib sulfate | CAPSULE;ORAL | 213756-002 | Apr 10, 2020 | RX | Yes | Yes | 12,364,684 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astrazeneca | KOSELUGO | selumetinib sulfate | CAPSULE;ORAL | 213756-001 | Apr 10, 2020 | RX | Yes | No | 7,425,637 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Astrazeneca | KOSELUGO | selumetinib sulfate | GRANULE;ORAL | 219943-002 | Sep 10, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
